Andecaliximab
Andecaliximab (pronounced an-de-kal-ix-i-mab) is a monoclonal antibody designed for the treatment of various types of cancer. It is a type of biological therapy that targets and binds to the matrix metalloproteinase 9 (MMP-9), a protein often found in high levels in tumors and associated with cancer progression.
Etymology
The name "Andecaliximab" follows the World Health Organization's guidelines for the nomenclature of monoclonal antibodies. The suffix "-mab" indicates it is a monoclonal antibody, while the infix "-lix-" suggests it targets the immune system.
Mechanism of Action
Andecaliximab works by binding to the MMP-9 protein, which is often overexpressed in cancerous tumors. By inhibiting the activity of this protein, Andecaliximab can slow down tumor growth and potentially shrink the tumor size.
Clinical Trials
Andecaliximab has been studied in several clinical trials, including those for gastric cancer and colorectal cancer. However, as of now, it is not yet approved by the Food and Drug Administration (FDA) for any specific use.
Related Terms
- Monoclonal Antibody
- Matrix Metalloproteinase 9 (MMP-9)
- Biological Therapy
- Cancer
- Clinical Trials
- Gastric Cancer
- Colorectal Cancer
External links
- Medical encyclopedia article on Andecaliximab
- Wikipedia's article - Andecaliximab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski